leisure time -WSS

leisure time

author：knowledge 2025-09-29 19:59:28 - browse：7

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： People can get long Covid without testing positive for virus: Study

hotspot

WSS

Bright Health sells Medicare Advantage business to Molina

Affirmative action in medical school literally saved lives

Former Pear Therapeutics executives start new VC firm

Abortion policy in the spotlight at Republican debate

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Continuity nursing helped my family in our darkest PICU moments

hotspot

leisure time

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Psychedelics group wrestles with new pharma identity

Apple is now the first public company to be valued at $3 trillion

CDC says it’s too soon to assess risk posed by Covid subvariant

Peter Hotez and the public health issue of online harassment

The high cost of giving birth even with insurance

In age of alternative facts, a scholarly course on calling out crap

23andMe had bad news about my health. I wish a person had delivered it

BioMarin wins approval for gene therapy to treat hemophilia A

FDA greenlights medical device to combat bladder issues

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Psychedelics group wrestles with new pharma identity

California store owner shot dead in dispute over displaying Pride flag: Police

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Intellia plays down concerns on accidental germline transmission

State Dept. review finds Biden bears some blame for Afghanistan failures

knowledge

leisure time

hotspot

hotspot